For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ABIOMED been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
ABIOMED is a member of the Medical sector. This group includes 763 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ABMD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ABMD's full-year earnings has moved 6.65% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ABMD has returned about 118.65% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 1.45% on a year-to-date basis. This means that ABIOMED is outperforming the sector as a whole this year.
Looking more specifically, ABMD belongs to the Medical - Instruments industry, a group that includes 88 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have lost 3.41% this year, meaning that ABMD is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on ABMD as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ABIOMED been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
ABIOMED is a member of the Medical sector. This group includes 763 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ABMD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ABMD's full-year earnings has moved 6.65% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ABMD has returned about 118.65% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 1.45% on a year-to-date basis. This means that ABIOMED is outperforming the sector as a whole this year.
Looking more specifically, ABMD belongs to the Medical - Instruments industry, a group that includes 88 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have lost 3.41% this year, meaning that ABMD is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on ABMD as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>